Linda M Rubinstein
CIK 1321937 · CHIEF FINANCIAL OFFICER · last filed 2025-12-10
Linda M Rubinstein is a CHIEF FINANCIAL OFFICER who has filed 11 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for ADVM, was dated Dec 10, 2025. Across all open-market trades the lifetime net is +$145.5K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ADVM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
100 CARDINAL WAY
REDWOOD CITY, CA 94063
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Adverum Biotechnologies, Inc. (ADVM) Delisted | CHIEF FINANCIAL OFFICER | 61,150 | $4.36 | $266.6K | $145.5K | 7 | 2025-12-10 |
| BIOCEPT INC (BIOC) Delisted | Director | — | $0.43 | — | $0 | 2 | 2022-09-08 |
Recent Filings
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-10 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Mixed | −20,525 | $204.8K | EDGAR |
| 2025-06-20 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Mixed | — | $0 | EDGAR |
| 2025-02-27 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | +8,125 | $0 | EDGAR |
| 2024-08-06 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-14 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-09-05 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-09 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Buy (P) | +100,000 | $145.5K | EDGAR |
| 2022-09-08 | BIOCEPT INC (BIOC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-07-20 | BIOCEPT INC (BIOC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-02-01 | — | Disp (D) | — | $0 |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.